AdultPediatricDosage Forms & Strengths tablet 5mg 7.5mg 10mg 15mg 30mg Anxiety Disorders 10-15 mg/day PO divided q8-12hr; may increase every 2-3 days by 5 mg/day to 15-30 mg/day PO divided q8-12hr; not to exceed 60 mg/day Smoking Cessation (Off-label) 30-60 mg/day PO for 9-13 weeks; begin 2-3 weeks before quit date Dosing Modifications Renal impairment: Not recommended for patients with severe impairment Hepatic impairment: Not recommended for patients with severe impairmentDosage Forms & Strengths tablet 5mg 7.5mg 10mg 15mg 30mg Generalized Anxiety Disorder (Off-label) Pre-adolescent: 2.5-5 mg PO qDay; may increase dose by 2.5 mg every 3-4 days; not to exceed 20 mg/day Adolescent: 5-10 mg PO qDay; may increase by 5 mg/day at weekly intervals PRN; not to exceed 60 mg/day divided q8-12hr Dosing Modifications Renal impairment: Not recommended for patients with severe impairment Hepatic impairment: Not recommended for patients with severe impairmentInteraction CheckerEnter a drug name and buspironeNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (6)isocarboxazidisocarboxazid and buspirone both increase serotonin levels. Contraindicated.isocarboxazid, buspirone. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.linezolidlinezolid, buspirone. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.phenelzinephenelzine and buspirone both increase serotonin levels. Contraindicated.phenelzine, buspirone. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.procarbazineprocarbazine and buspirone both increase serotonin levels. Contraindicated. Combination is contraindicated within 2 weeks of MAOI use.procarbazine, buspirone. Other (see comment). Contraindicated. Comment: Concomitant use of buspirone with MAOIs can increase blood pressure; this combination should be avoided.selegiline transdermalselegiline transdermal, buspirone. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.tranylcyprominetranylcypromine and buspirone both increase serotonin levels. Contraindicated.tranylcypromine, buspirone. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.Serious - Use Alternative (58)abametapirabametapir will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. If not feasible, avoid use of abametapir.amitriptylineamitriptyline and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.amoxapineamoxapine and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.apalutamideapalutamide will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed.benzhydrocodone/acetaminophenbenzhydrocodone/acetaminophen, buspirone. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.carbamazepinecarbamazepine will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.cimetidinecimetidine will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.citalopramcitalopram and buspirone both increase serotonin levels. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.clarithromycinclarithromycin will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.clomipramineclomipramine and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.desipraminedesipramine and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.desvenlafaxinebuspirone and desvenlafaxine both increase serotonin levels. Avoid or Use Alternate Drug.dextromethorphanbuspirone and dextromethorphan both increase serotonin levels. Avoid or Use Alternate Drug.doxepindoxepin and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.duloxetineduloxetine and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.erythromycin baseerythromycin base will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.erythromycin ethylsuccinateerythromycin ethylsuccinate will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.erythromycin lactobionateerythromycin lactobionate will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.erythromycin stearateerythromycin stearate will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.escitalopramescitalopram and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.fexinidazolefexinidazole will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates.fluoxetinefluoxetine and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.fluvoxaminefluvoxamine and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.hydrocodonehydrocodone, buspirone. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.idelalisibidelalisib will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substratesimipramineimipramine and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.ivosidenibivosidenib will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternate therapies. If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs.levomilnacipranlevomilnacipran and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.linezolidlinezolid and buspirone both increase serotonin levels. Avoid or Use Alternate Drug. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first.lofepraminelofepramine and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.lonafarniblonafarnib will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration with sensitive CYP3A substrates. If coadministration unavoidable, monitor for adverse reactions and reduce CYP3A substrate dose in accordance with product labeling.lopinavirlopinavir will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.lorcaserinbuspirone and lorcaserin both increase serotonin levels. Avoid or Use Alternate Drug.maprotilinemaprotiline and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.meperidinebuspirone and meperidine both increase serotonin levels. Avoid or Use Alternate Drug.methylene bluemethylene blue and buspirone both increase serotonin levels. Avoid or Use Alternate Drug. Methylene blue may increase serotonin as a result of MAO-A inhibition. If methylene blue must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last methylene blue dose or after 2 weeks of monitoring, whichever comes first.metoclopramide intranasalbuspirone, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.milnacipranmilnacipran and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.nefazodonenefazodone and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.nortriptylinenortriptyline and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.olopatadine intranasalbuspirone and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. paroxetineparoxetine and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.protriptylineprotriptyline and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.rasagilinerasagiline, buspirone. Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of acute hypertensive episode. Avoid combination within 14 days of MAOI use.rifabutinrifabutin will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.rifampinrifampin will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.selegilineselegiline and buspirone both increase serotonin levels. Avoid or Use Alternate Drug. Concurrent use is not recommended. Risk of acute hypertensive episodes.selegiline transdermalselegiline transdermal and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.selinexorselinexor, buspirone. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.sertralinesertraline and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.St John's WortSt John's Wort will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.buspirone and St John's Wort both increase serotonin levels. Avoid or Use Alternate Drug.sufentanil SLsufentanil SL, buspirone. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may result in hypotension, profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.trazodonetrazodone and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.trimipraminetrimipramine and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.tucatinibtucatinib will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If unavoidable, reduce CYP3A substrate dose according to product labeling.venlafaxinevenlafaxine and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.vilazodonebuspirone, vilazodone. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug. Concomitant therapy should be discontinued immediately if signs or symptoms of serotonin syndrome emerge and supportive symptomatic treatment should be initiated. .voxelotorvoxelotor will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid.Monitor Closely (131)5-HTP5-HTP and buspirone both increase serotonin levels. Modify Therapy/Monitor Closely.almotriptanalmotriptan and buspirone both increase serotonin levels. Modify Therapy/Monitor Closely.amobarbitalamobarbital will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.aprepitantaprepitant will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.armodafinilarmodafinil will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.artemether/lumefantrineartemether/lumefantrine will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.atazanaviratazanavir will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.belzutifanbelzutifan will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If unable to avoid coadministration of belzutifan with sensitive CYP3A4 substrates, consider increasing the sensitive CYP3A4 substrate dose in accordance with its prescribing information. bosentanbosentan will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.brexanolonebrexanolone, buspirone. Either increases toxicity of the other by sedation. Use Caution/Monitor.budesonidebudesonide will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.buprenorphine, long-acting injectionbuspirone increases toxicity of buprenorphine, long-acting injection by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of buprenorphine and benzodiazepines or other CNS depressants increases risk of adverse reactions including overdose, respiratory depression, and death. Cessation of benzodiazepines or other CNS depressants is preferred in most cases. In some cases, monitoring at a higher level of care for tapering CNS depressants may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate.butabarbitalbutabarbital will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.butalbitalbutalbital will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.cenobamatecenobamate will decrease the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate.cenobamate, buspirone. Either increases effects of the other by sedation. Use Caution/Monitor.ceritinibceritinib will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.cobicistatcobicistat will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. A decreased dose of buspirone may be requiredcocaine topicalbuspirone